Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

SOHO 2020 | Sagar Lonial on SOHO 2020

Sagar Lonial • 27 Aug 2020
SOHO 2020
General

Sagar Lonial, MD, FACP, of Winship Cancer Institute of Emory University, Atlanta, GA, and chair of the upcoming Society of Hematologic Oncology (SOHO) 2020 virtual meeting discusses what to expect from this educational, research-led meeting. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Sagar Lonial

Phase III EXCALIBER-RRMM trial results: iberdomide plus daratumumab in R/R multiple myeloma
0:53
Phase III EXCALIBER-RRMM trial results: iberdomide plus daratumumab in R/R multiple myeloma
Sagar Lonial • 24 Sep 2026
IberDd in patients with newly diagnosed myeloma: a subgroup analysis by renal function
0:58
IberDd in patients with newly diagnosed myeloma: a subgroup analysis by renal function
Sagar Lonial • 7 Dec 2025
HRQoL with belantamab mafodotin treatment in patients with R/R myeloma in the DREAMM-7 trial
1:40
HRQoL with belantamab mafodotin treatment in patients with R/R myeloma in the DREAMM-7 trial
Sagar Lonial • 7 Dec 2025
Practical advice for physicians treating patients with myeloma using belantamab mafodotin
0:37
Practical advice for physicians treating patients with myeloma using belantamab mafodotin
Sagar Lonial • 16 May 2025

Related Videos

From immunosuppression to targeted immunomodulation: emerging treatment strategies in GvHD
2:58
From immunosuppression to targeted immunomodulation: emerging treatment strategies in GvHD
Iskra Pusic • 11 Sep 2026
Three-year survival update of pre-induction azacitidine and venetoclax in newly diagnosed AML
3:46
Three-year survival update of pre-induction azacitidine and venetoclax in newly diagnosed AML
Maher Salamoon • 8 Sep 2026
Understanding the risks of lymphoproliferative disorders following CAR T-cell therapy
2:01
Understanding the risks of lymphoproliferative disorders following CAR T-cell therapy
Michael Jain • 11 Sep 2026
Long-term survivorship after CAR T-cell therapy: addressing non-relapse mortality
1:46
Long-term survivorship after CAR T-cell therapy: addressing non-relapse mortality
Michael Jain • 11 Sep 2026
The content of VJHemOnc is intended for healthcare professionals